Drug safety evaluation of rotigotine

Bibliography

• Belluzzi JD, Domino EF, May JM, N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 1994;9:147-54
   PubMed Web of Science ®Google Scholar
• Horn AS, Tepper P, Van der Weide J, Synthesis and radioreceptor binding activity of N-0437, a new, extremely potent and selective D2 dopamine receptor agonist. Pharm Weekbl Sci 1985;7:208-11
   PubMedGoogle Scholar
• Van der Weide J, Tendijck ME, Tepper PG, The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors. Eur J Pharmacol 1988;146:319-26
   PubMed Web of Science ®Google Scholar
• Timmerman W, Westerink BH, De Vries JB, Microdialysis and striatal dopamine release: stereoselective actions of the enantiomers of N-0437. Eur J Pharmacol 1989;162:143-50
   PubMed Web of Science ®Google Scholar
• Swart PJ, De Zeeuw RA. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie 1992;47:613-15
   PubMed Web of Science ®Google Scholar
• Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005;65:S3-5
   PubMedGoogle Scholar
• Pfeiffer RF. A promising new technology for Parkinson's disease. Neurology 2005;65:S6-10
   Google Scholar
• Guldenpfennig WM, Poole KH, Sommerville KW, Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 2005;28:106-10
   PubMed Web of Science ®Google Scholar
• Baldwin CM, Keating GM. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease. CNS Drugs 2007;21:1039-55
   PubMed Web of Science ®Google Scholar
• Boroojerdi B, Wolff HM, Braun M, Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. Drugs Today (Barc) 2010;46:483-505
   PubMed Web of Science ®Google Scholar
• Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009;37:2055-60
   PubMed Web of Science ®Google Scholar
• Braun M, Cawello W, Andreas JO, Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. J Clin Pharmacol 2009;49:1047-55
   PubMed Web of Science ®Google Scholar
• Hansen K, Braun M, Horstmann R. Low drug-drug interaction potential of rotigotine [abstract]. J Clin Pharmacol 2005;45:1091
   Web of Science ®Google Scholar
• Cawello W, Wolff HM, Meuling WJ, Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. Clin Pharmacokinet 2007;46:851-7
   PubMed Web of Science ®Google Scholar
• Braun M, Cawello W, Poole KH, Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease. Eur J Neurol 2005;12(Suppl 2):96
   Google Scholar
• Cawello W, Braun M, Horstmann R. Impact of moderate impairment of hepatic function on steady-state pharmacokinetics of transdermal rotigotine. Eur J Neurol 2007;14(Suppl 1):199
   PubMedGoogle Scholar
• Cawello W, Braun M, Horstmann R. Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function. J Clin Pharmacol 2005;45:1091
   Web of Science ®Google Scholar
• Braun M, Cawello W, Boekens H, Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol 2009;67:209-15
   PubMed Web of Science ®Google Scholar
• Braun M, Elshoff JP, Andreas JO, Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive. Br J Clin Pharmacol 2009;68:386-94
   PubMed Web of Science ®Google Scholar
• Scheller D, Ullmer C, Berkels R, The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009;379:73-86
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C, Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-6
   PubMed Web of Science ®Google Scholar
• PSG. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-8
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Korczyn AD, Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-404
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68:1262-7
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-9
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N, Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-20
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010;11:848-56
   PubMed Web of Science ®Google Scholar
• Hening WA, Allen RP, Ondo WG, Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010;25:1675-83
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008;9:228-39
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Benes H, Poewe W, Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H. Garcia-Borreguero, et al. Long-term safety and efficacy of rotigotine transdermal system in moderate to severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011;10(8):710-20
   PubMed Web of Science ®Google Scholar
• Hogl B, Oertel WH, Stiasny-Kolster K, Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC Neurol 2010;10:86
   PubMed Web of Science ®Google Scholar
• Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial. BMC Neurol 2007;7:20
   PubMed Web of Science ®Google Scholar